Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Patent
1997-09-30
1999-01-12
Henley, III, Raymond
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
A61K 3156
Patent
active
058589988
ABSTRACT:
According to the invention it was unexpectedly found that budesonide can be used for the treatment of cholestatic liver diseases such as PBC, PSC and AC. In particular budesonide is highly effective when administered together with ursodeoxycholic acid.
REFERENCES:
patent: 3929768 (1975-12-01), Brattsand et al.
patent: 4917898 (1990-04-01), Angelico et al.
patent: 5079240 (1992-01-01), Hofmann
patent: 5234697 (1993-08-01), Sipos
patent: 5262172 (1993-11-01), Sipos
patent: 5300300 (1994-04-01), Egidio et al.
patent: 5352460 (1994-10-01), Sipos
patent: 5405621 (1995-04-01), Sipos
patent: 5643602 (1997-07-01), Ulmius
patent: 5739161 (1998-04-01), Ueno
Abstract of European Patent Application No. 269516 (Poupon), published Jun. 1, 1988, from Derwent Information, Ltd., 1 page, (1995).
Abstract of Japanese Patent Application No. 61158995 (Shironaga), published Jul. 18, 1986, from ACS, 1 pg., (1995).
Abstract of Japanese Patent Application No. 04235918 (Katagiri), published on Aug. 25, 1992, from ACS, 1 pg., (1995).
"Wichtige Neuerungen bei Hepatitiden und Cholestatischen Lebererkrankungen", Aktuelle Wissenschaft fur Klinik und Praxis, Satellitensymposium Aktuelle Hepatologie--Diagnostische und Therapeutische Fortschritte 1997, p. 3, (Apr. 1997).
Atkinson, J., et al., "Human Myofibroblastic Ito-Cells (MFI) Receive Growth Signals from Collagen VI (CVI)", Falk Symposium 87, Poster 301, 1 pg., (1995).
Bode, J.C., "Klinik und Therapie alkoholischer Leberschaden", from : Handbuch Alkohol Alkoholismus Alkoholbedingte Organschaden, Johan Ambrosius Barth, publ., Leipzig, 237-259 (Ch. 11), (1995).
Danielsson, A., et al., "Oral Budenoside for Treatment of Autoimmune Chronic Active Hepatitis", Aliment Pharmacol Ther, 8, 585-590, (1994).
Heathcote, E.J., et al., "Combined Analysis of French, American, and Canadian Randomized Controlled Trials of Ursodeoxycholic Acid Therapy in Primary Biliary Cirrhosis", Gastroenterology, 108 (supplement), p. A 1082, (Apr. 1995).
Kaplan, M.M., "Medical Approaches to Primary Sclerosing Cholangitis", Seminars in Liver Disease, 11, 56-63, (1991).
Leuschner, U., "Gallensauren zur Therapie von Lebererkrankungen", Internist, 35, 1147-1155, (1994).
Leuschner, U., et al., "Effects of Ursodeoxycholic Acid After 4 to 12 Years of Therapy in Early and Late Stages of Primary Biliary Cirrhosis", Journal of Hepatology, 21, 624-633, (1994).
Leuschner, U., et al., "Ursodeoxycholic Acid in Combination with Prednisolone or Budenoside in the Therapy of Primary Biliary Cirrhosis", Proceedings of the Falk Symposium No. 93, Bile Acids in Hepatobiliary Diseases: Basic Research and Clinical Application (Oct. 1996 Meeting), ed. G. Paumgartner et al., Kluwar Academic Publishers, Netherlands, 299-302, (1997).
Leuschner, U., et al., "Ursodeoxycholic Acid in Primary Biliary Cirrhosis: Results of a Controlled Double-Blind Trial", Gastroenterology, 97, 1268-1274, (1989).
Mitchison, H.C., et al., "A Controlled Trial of Prednisolone Treatment in Primary Biliary Cirrhosis: Three Year Results", Journal of Hepatology, 15, 336-344, (1992).
Mitchison, H.C., et al., "A Pilot, Double-Blind, Controlled 1-Year Trial of Prednisolone Treatment in Primary Biliary Cirrhosis: Hepatic Improvement but Greater Bone Loss", Hepatology, 10, 420-429, (1989).
Morgan, T.R., "Treatment of Alcoholic Hepatitis", Seminars in Liver Disease, 13, 384-394, (1993).
Neuman, M.G., et al., "Effect of Tauroursodeoxycholic and Ursodeoxycholic Acid on Ethanol-induced Cell Injuries in the Human Hep G2 Cell Line", Gastroenterology, 109, 555-563, (1995).
Nolan, J.P., "Intestinal Endotoxins as Mediators of Hepatic Injury--An Idea Whose Time Has Come Again", Hepatology, 10, 887-891, (1989).
Paumgartner, G., et al., "Biliary Liver Diseases: Diagnosis, Natural Course and Therapy", from : Falk Symposium 87, Acute and Chronic Liver Diseases, ed. R. Schmid et al., Kluwar Academic Publishers, Netherlands, 96-106 (Ch. 8), 1996.
Poupon, R.E., et al., "A Multicenter, Controlled Trial of Ursodiol for the Treatment of Primary Biliary Cirrhosis", N. Eng. J. Med., 324, 1548-1554, (1991).
Poupon, R.E., et al., "Ursodiol for the Long-term Treatment of Primary Biliary Cirrhosis", New England Journal of Medicine, 330, 1342-1347, (May 12, 1994).
Rasenack, J., et al., "Primar Biliare Zirrhose, Primar Sklerosierende Cholangitis und Syndrome mit Schwund der Gallengange", from : Hepatologie, eds. W. Gerok and H. Blum, Urban & Schwarzenberg, publ., Munich, 426-439 (Ch. 22), (1995).
Schonfeld, J.V., et al., "Primar Biliare Zirrhose (PBS)", from : Praktische Gastroenterologie, ed. P. Layer et al., Urban & Schwarzenberg, publ., Munich, 396-399 and 452-457, (1996).
Schwarzenberg, S.J., et al., "Ursodeoxycholic Acid Modifies Gut-Derived Endotoxemia in Neonatal Rats", Pediatric Research, 35, 214-217, (1994).
Simko, V., et al., "Ursodeoxycholic Therapy in Chronic Liver Disease: A Meta-Analysis in Primary Biliary Cirrhosis and in Chronic Hepatitis", American Journal of Gastroenterology, 89, 392-398, (1994).
Sonnenborn, U., et al., "Beziehungen zwischen Wirtsorganismus und Darmflora", S. 38-39, (1991).
Stiehl, A., et al., "Medical Treatment of Primary Sclerosing Cholangitis: On the of Ursodeoxycholic Acid", Proceedings of the Falk Symposium No. 93, Bile Acids in Hepatobiliary Diseases: Basic Research and Clinical Application (Oct. 1996 Meeting), ed. G. Paumgartner et al., Kluwar Academic Publishers, Netherlands, 306-314, (1997).
Hoffman, J.C., et al., "Detection of a Soluble Form of the Human Adhesion Receptor Lymphocyte Function-Associated Antigen-3 (LFA-3) in Patients With Chronic Liver Disease", Journal of Hepatology, 25, 465-473, (1996).
Larusso, N., "Search for Medical Treatment for Primary Biliary Cirrhosis", Lancet, 350, 1046, (1997).
Rambusch, E.G., et al., "Immunsuppressive Therapie der Autoimmunen Lebererkrankungen", Internist, 38, 574-581, (1997).
Dr. Falk Pharma GmbH
Henley III Raymond
LandOfFree
Budesonide alone or in combination with ursodeoxycholic acid in does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Budesonide alone or in combination with ursodeoxycholic acid in , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Budesonide alone or in combination with ursodeoxycholic acid in will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1516169